Teleflex (NYSE:TFX) PT Raised to $235.00

Teleflex (NYSE:TFX) had its price objective raised by analysts at Truist Financial from $219.00 to $235.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price objective would indicate a potential upside of 6.54% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Piper Sandler raised Teleflex from a “neutral” rating to an “overweight” rating and upped their target price for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $262.43.

Teleflex Price Performance

Shares of TFX opened at $220.58 on Tuesday. The stock’s 50 day moving average is $208.62 and its two-hundred day moving average is $224.04. The firm has a market capitalization of $10.39 billion, a PE ratio of 35.41, a P/E/G ratio of 2.05 and a beta of 1.13. The company has a current ratio of 2.51, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. Teleflex has a twelve month low of $177.63 and a twelve month high of $262.97.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.14. Teleflex had a return on equity of 14.78% and a net margin of 9.82%. The firm had revenue of $737.80 million for the quarter, compared to analyst estimates of $726.85 million. During the same quarter in the prior year, the company earned $3.09 EPS. Teleflex’s revenue was up 3.8% on a year-over-year basis. Research analysts anticipate that Teleflex will post 13.75 earnings per share for the current year.

Institutional Trading of Teleflex

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC increased its holdings in shares of Teleflex by 22.9% during the 2nd quarter. CWM LLC now owns 1,317 shares of the medical technology company’s stock worth $277,000 after buying an additional 245 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Teleflex by 20,700.0% during the 2nd quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock worth $44,000 after buying an additional 207 shares during the last quarter. DNB Asset Management AS increased its holdings in shares of Teleflex by 5.2% during the 2nd quarter. DNB Asset Management AS now owns 7,584 shares of the medical technology company’s stock worth $1,595,000 after buying an additional 376 shares during the last quarter. Westwood Holdings Group Inc. increased its holdings in shares of Teleflex by 25.3% during the 1st quarter. Westwood Holdings Group Inc. now owns 57,225 shares of the medical technology company’s stock worth $12,943,000 after buying an additional 11,569 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Teleflex by 2.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 7,290 shares of the medical technology company’s stock worth $1,606,000 after buying an additional 180 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.